Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the call over to Helen Rubenstein, Vice President of Investor Relations and Corporate Strategy at Numora. Please go ahead. Good afternoon, and thank you for joining Numora Therapeutics' fourth quarter and full year 2025 Financial Results Conference Call. Before we begin, I encourage everyone to visit the Investors and Media section of our website at numoratx.com, where you can find the press release related to today's call. With me on the call today are Chief Executive Officer Paul Burns, President Josh Pinto, Chief Operating and Development Officer Bill Arora, Chief Scientific Officer Nick Brandon, and Chief Financial Officer Mike Milligan. I'd like to point out that we will be making forward-looking statements during today's call which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional detail. With that, I'll now turn the call over to Paul. Thanks, Helen. Good morning, everyone, and thank you for joining us. 2025 marked a year of important clinical progress and execution for Pneumora. We made meaningful strides in advancing our diverse pipeline of novel mechanism therapies, reported compelling data for NMRA 511, our oral highly potent brain penetrant and selective vasopressin 1A receptor antagonist, progressed our phase three program for Novacropran with optimizations based on key learning...